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Phospho-Smad1/5/8TBX20 gain-of-function mutations in humans are associated with congenital heart malformations and
myocardial defects. However the effects of increased Tbx20 function during cardiac chamber development
and maturation have not been reported previously. CAG-CAT-Tbx20 transgenic mice were generated for
Cre-dependent induction of Tbx20 in myocardial lineages in the developing heart. βMHCCre-mediated
overexpression of Tbx20 in fetal ventricular cardiomyocytes results in increased thickness of compact
myocardium, induction of cardiomyocyte proliferation, and increased expression of Bmp10 and pSmad1/5/8 at
embryonic day (E) 14.5. βMHCCre-mediated Tbx20 overexpression also leads to increased expression of cardiac
conduction system (CCS) genes Tbx5, Cx40, and Cx43 throughout the ventricular myocardium. In contrast,
Nkx2.5Cre mediated overexpression of Tbx20 in the embryonic heart results in reduced cardiomyocyte
proliferation, increased expression of a cell cycle inhibitor, p21CIP1, and decreased expression of Tbx2, Tbx5,
and N-myc1 at E9.5, concomitant with decreased phospho-ERK1/2 expression. Together, these analyses
demonstrate that Tbx20 differentially regulates cell proliferation and cardiac lineage speciﬁcation in embryonic
versus fetal cardiomyocytes. Induction of pSmad1/5/8 at E14.5 and inhibition of dpERK expression at E9.5 are
consistent with selective Tbx20 regulation of these pathways in association with stage-speciﬁc effects on
cardiomyocyte proliferation. Together, these in vivo data support distinct functions for Tbx20 in regulation of
cardiomyocyte lineage maturation and cell proliferation at embryonic and fetal stages of heart development.
© 2012 Elsevier Inc. All rights reserved.Introduction
T-box (Tbx) transcription factors are critical regulators of heart
development, and mutations in several TBX genes in humans are
associated with congenital cardiac anomalies (Plageman and Yutzey,
2005; Stennard and Harvey, 2005). Tbx20, a member of the Tbx1
subfamily of T-box genes, is expressed in multiple organs, including
the developing heart (Plageman and Yutzey, 2004; Stennard et al.,
2003; Takeuchi et al., 2003). Mutations in human TBX20 that result
in gain or loss of protein function are associated with a wide array
of cardiac malformations, including septal defects, defects in valvulo-
genesis, and cardiomyopathy (Kirk et al., 2007; Posch et al., 2010). In
mice, systemic loss of Tbx20 results in lethality by embryonic day (E)
10.5, associated with reduced myocardial proliferation and inhibition
of chamber differentiation (Cai et al., 2005; Singh et al., 2005;
Stennard et al., 2005; Takeuchi et al., 2005). Direct downstream target
genes of Tbx20 in the primitive myocardium include Tbx2 and N-myc1,on of Molecular Cardiovascular
, 240 Albert Sabin Way, Cincin-
utzey).
rights reserved.that function to regulate cardiomyocyte proliferation (Cai et al.,
2005). In adult mice, heterozygous loss of Tbx20 leads to dilated
cardiomyopathy (Stennard et al., 2005) and conditional homozygous
loss of Tbx20 in cardiomyocytes results in severe cardiomyopathy
with associated arrhythmias and death (Shen et al., 2011). However,
the speciﬁc functions of Tbx20 in the developing myocardium after
the initial stages of heart chamber speciﬁcation have not been deﬁned
in vivo.
During embryonic and fetal development, multiple regulatory
pathways control differential rates of cardiomyocyte proliferation
necessary for proper cardiac chamber morphogenesis and function
(Sedmera and Thompson, 2011). During embryonic stages of
chamber morphogenesis (mouse E9.5-E11.5), Neuregulin1 (Nrg1),
an endocardium-derived mitogen, promotes the initiation of
trabecular myocardial outgrowth and cardiomyocyte proliferation
via ErbB receptors and ERK/MAP-kinase activation (Lai et al., 2010;
Stennard et al., 2005; Woldeyesus et al., 1999). During formation of
the ventricular compact layer at fetal stages (E12.5–E17.5), Bmp10
signaling through pSmad1/5/8 activation is required for ventricular
cardiomyocyte proliferation, and cardiomyocyte-speciﬁc loss of
Smad4, necessary for BMP signaling, leads to myocardial hypoplasia
with decreased expression of N-myc1, cyclinD1, and cyclinD2 (Chen
et al., 2004; Song et al., 2007). A critical difference in regulation of
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cardium, which is a source of several mitogens, including IGF2 and
FGF9, that promote fetal ventricular compact layer cell proliferation
(Lavine et al., 2005; Li et al., 2011; Sucov et al., 2009). Thus, multiple
signaling pathways have been implicated in the regulation of
cardiomyocyte proliferation in the developing heart. However, less is
known about the contributions of speciﬁc transcription factors or the
mechanisms of integration of these pathways in the control of
differential rates of proliferation during cardiac organogenesis.
Transgenicmicewere generatedwith Cre-dependent overexpression
of Tbx20 in embryonic or fetal cardiomyocytes. Induction of Tbx20
expression in the fetal ventricles (E12.5–E17.5) with βMHCCre results
in increased cell proliferation, with increased expression of N-myc1,
Bmp10, and pSmad1/5/8, as well as increased expression of conduction
system markers Tbx5, Cx40, and Cx43 throughout the ventricular
myocardium. In contrast, induction of Tbx20 expression in the embryonic
heart (E9.5) with Nkx2.5Cre results in a small heart with decreased cell
proliferation, apparently normal induction of chamber maturation gene
expression, and attenuated activation of ERK1/2 MAPK. Thus, Tbx20
overexpression has opposite effects on cardiomyocyte cell proliferation
and lineage maturation in embryonic and fetal cardiomyocytes that is
associatedwith differential regulation of ERK1/2 and Smad1/5/8 signaling
in vivo.Materials and methods
Generation of transgenic mice
The Cre-responsive transgene CAG-CAT-Tbx20 (CC-Tbx20) was
constructed by modiﬁcation of the CAG-CAT-Z construct, which
contains a CMV enhancer and chicken β-actin gene (CAG) promoter,
linked to the chloramphenicol acetyltransferase (CAT) gene, ﬂanked by
loxp sites (Araki et al., 1995). The full-length murine Tbx20 coding
sequence was isolated from pAC-CMV-Tbx20 (Plageman and Yutzey,
2004) and inserted into the BamH1 site of CAG-CAT-Z in place of LacZ
(Araki et al., 1995). The Tbx20 transgene consists of the Tbx20a isoform
that includes both transactivation and transrepression domains
(Stennard et al., 2003). This isoform is preferentially expressed in the
cardiac OFT region at E9.5–E12.5, although expression is detected
throughout the primitive heart tube at E9.5–E10.5 (Takeuchi et al.,
2005). Successful insertion of the full-length murine Tbx20 coding
sequence was veriﬁed by direct sequencing of the CC-Tbx20 transgenic
construct. The puriﬁed linearized construct was introduced by pronu-
clear microinjection of fertilized blastocysts of FVBN mice. Transgenic
founder lines were validated by genotyping using CAG-CAT (5′-TCA
CTG CAT TCT AGT TGT GGT TTG-3′) and Tbx20 (5′-TTG GAC TCA GGA
TCC ACT CC-3′) speciﬁc primers. Transgene expression in multiple
organs was conﬁrmed by the presence of CAT protein detected by
CAT-ELISA assay (Roche, #11363727001, used as per manufacturer's
protocols) in two independent founder lines. The founder line with
robust expression of CAT protein in the heart was used for all subse-
quent in vivo transgenic analyses. Female CAG-CAT-Tbx20 mice were
bred with βMHCCre (Parsons et al., 2004) or Nkx2.5Cre (Moses et al.,
2001) males to generate double transgenic embryos, neonates, and
adult offspring. Timed matings were established, with the morning of
an observed copulation plug set at E0.5. All studies were performed
on cohorts of βMHCCre;CC-Tbx20, or Nkx2.5Cre;CC-Tbx20, double
transgenic (DTG) animals compared to single transgenic (STG) CC-
Tbx20 littermate controls. Genotyping for βMHCCre (Parsons et al.,
2004) and Nkx2.5Cre (Moses et al., 2001) was performed as described
previously by PCR of genomic DNA isolated from embryonic yolk sacs
or 3 weeks postnatal tail clips. All experiments involving animals were
carried out with experimental protocols and procedures reviewed and
approved by the Cincinnati Children's Medical Center Institutional
Biosafety Committee and Institutional Animal Care and Use Committee.In situ hybridization (ISH) and immunohistochemistry
Whole embryos isolated at E9.5 or E14.5 and hearts isolated at E17.5
were collected and processed for either in situ hybridization (ISH) or
immunohistochemistry as previously described (Chakraborty et al.,
2008, 2010; Lincoln et al., 2006). The generation of antisense RNA
probes and ISH was performed as previously described (Chakraborty
et al., 2008). The plasmids for generation of Bmp10 (Chen et al., 2004),
Nppa, Smpx, Tbx2, Cx40, Cx43 (Christoffels et al., 2004), Tbx5 (Takeuchi
et al., 2005), N-myc1 (Cai et al., 2005) and MLC2v (Liberatore et al.,
2000) antisense RNA probes were used as previously described. For
histology, tissueswere deparafﬁnized and dehydrated through a graded
ethanol series, followed by staining with Hematoxylin and Eosin (H&E)
as previously described (Hinton et al., 2006).
The following antibodies were used for immunoﬂuorescence (IF)
and/or colorimetric immunohistochemistry with diaminobenzidine
(DAB) detection: Phospho-Histone H3 (pHH3) (1:100; Millipore,
06–570), MF20 (1:200; Developmental Studies Hybridoma Bank,
University of Iowa), pSmad1/5/8 (1:100; Millipore, AB3848), Tbx20
(1:100; Orbigen, PAB 11248), p21CIP1 (BD Pharmigen, 556430),
Diphosphorylated ERK-1/2 (dpERK) (1:10000; Sigma, M 8159) and
Twist1 (1:50; Santa Cruz, SC 81417). IF and colorimetric detection
methods were performed essentially as previously described
(Chakraborty et al., 2010). For IF, Alexa Fluor 488 (green)- and/or
568 (red)-conjugated goat anti-rabbit or goat anti-mouse secondary
antibodies (Molecular Probes, 1:100) were used with ToPro3
(Molecular Probes, 1:1000) for visualization of nuclei. Fluorescence
was visualized using a Zeiss LSM 510 confocal microscope and LSM
version 3.2 SP2 software. For colorimetric immunohistochemistry,
primary antibodies were detected using the Ultra-sensitive ABC
rabbit (anti-Tbx20) or mouse (anti-Twist1, -dpERK) IgG staining kit
according to manufacturer's suggested guidelines (Thermo Scientiﬁc,
32054 and 32052). Antibody staining was visualized using the metal
enhanced DAB substrate staining kit (Thermo Scientiﬁc, 34065).
β-galactosidase (β-gal) detection
β-gal expression was analyzed in whole (E12.5) and bisected
hearts (E14.5 and E17.5) using X-gal detection of β-gal activity as
previously described (Lincoln et al., 2004; Searcy et al., 1998). For
histology, X-gal stained embryos (E12.5) or bisected hearts (E14.5
and E17.5) were dehydrated through a graded isopropanol/PBT series
and parafﬁn wax embedded. Ten µm sections were cut, deparafﬁnized
in two changes in xylene for 5 min each and mounted in Cytoseal 60
(Richard-Allen Scientiﬁc) for microscopy and imaging.
RNA isolation and real-time quantitative RT-PCR (qRT-PCR)
Hearts were isolated from E9.5 embryos, and ventricles were
isolated from E14.5 and E18.5 embryos generated from multiple
matings of CC-Tbx20 females and Cre (βMHC or Nkx2.5) males. After
PCR genotyping, tissue from 4–6 early (E9.5 and E14.5) or 2–3 late
(E18.5) embryos was pooled for RNA isolation, and real time qRT-
PCR was performed as previously described (Chakraborty et al.,
2008, 2010). Forward and reverse primer sequences designed for
qRT-PCR are Nppa (5′-GTG AGC AGA CTG AGG AAG CA-3′ and 5′-
TGC TTT TCA AGA GGG CAG AT-3′); Tbx5 (5′-ATG GTC CGT AAC TGG
CAA AG-3′ and 5′-TTT CGT CTG CTT TCA CGA TG-3′); Cx40 (5′-CCT
GGA TAC CCT GCA TGT CT-3′ and 5′-GCT GTC GGA TCT TCT TC AG-
3′); Cx43 (5′-GAA CAC GGC AAG GTG AAG AT-3′ and 5′- GA CGA
GAG ACA CCA AGG AC-3′); N-myc1 (5′-CAG CTG CAC CGC GTC CAC
CA-3′ and 5′-CAT GCA GTC CTG AAG GAT GA-3′); Bmp10 (5′-ACC
AGA CGT TGG CAA AAG TCA GGC-3′ and 5′-GAT GAT CCA GGA GTC
CCA CCC AAT-3′); and Tbx2 (5′-TGA CAA GCA TGG CTT TAC CA-3′
and 5′-GTA GGC AGT GAC AGC GAT GA-3′). The primer sequences
for p21CIP1, p27KIP1 (Evans-Anderson et al., 2008), Cyclin A2 (Gurtner
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2010), Mlc2v, Smpx (Lai et al., 2010) and Nrg1 (Kato et al., 2010)
qRT-PCR were described previously. All the ampliﬁcation reactions
were performed with 34 cycles of 94 °C for 30 s; 55 °C for 45 s; and
72 °C for 30 s. A standard curve was generated for each primer pair
using E9.5 or E14.5 whole embryo-derived cDNA, and all the values
were normalized to ribosomal protein L7 expression (Hemmerich
et al., 1993). For each gene, normalized expression in STG tissue is
set to 1 and then the fold-change is calculated for corresponding
DTG samples. qRT-PCR results represent three independent samples
(biological 3X) performed in triplicate (technical 3X). Statistical
signiﬁcance of observed differences was determined by Student's t-
test (pb0.01).
Protein isolation and Western blotting
Protein lysates were isolated from E9.5, E12.5 E14.5, and E17.5
whole hearts using ice-cold CelLytic MT tissue lysis buffer (Sigma),
containing protease inhibitor mixture (Pierce) and phosphatase
inhibitor (Pierce) according to manufacturer's guidelines. After PCR
genotyping, hearts from 6–8 early (E9.5 and E12.5) or 2–3 late
(E14.5 and E17.5) embryos were pooled for total protein isolation,
and Western blots were performed as described previously
(Chakraborty et al., 2010). Immunoblots were developed using
chemiﬂuorescent detection with the Vistra ECF reagent (Amersham
Biosciences) and scanned using a Storm 860 phosphorimager
(Amersham Biosciences). Signal intensities were quantiﬁed with
ImageQuant 5.0 software (GE Healthcare). Tbx20 (1:500; Orbigen,
PAB 11248), pSmad 1/5/8 (1:500; Millipore, AB3848), ERK (1:1000;
Cell Signaling, 9102) and p-ERK (1:1000; Cell Signaling, 9101) primary
antibodies were used for immunoblot analysis. GAPDH (1:4000; Santa
Cruz) antibody reactivity was used as a loading control. Statistical
signiﬁcance was determined by Student's t-test (pb0.05).
Quantitative analyses of cell density, ventricular wall thickness, and cell
proliferation
The average number of cell nuclei per area of compact myocardium
and left ventricular wall thickness were determined using ImageJ
software (NIH).Measurementswere taken onH&E stained photomicro-
graphs of 5–6 tissue sections per heart from at least 4 hearts per
genotype. Proliferative indices of cardiomyocytes were calculated as
the total number of pHH3 nuclei in MF20-positive cardiomyocytes/
total number of nuclei in MF20-positive cardiomyocytes. Likewise, the
number of Tbx20 nuclei inMF20-positive cardiomyocytes/total number
of nuclei in MF20-positive cardiomyocytes was determined as a
quantitative measure of Tbx20 overexpression in Nkx2.5Cre mice. At
least 250 cell nuclei were counted from each heart section showing LV
or RV chamber myocardium. Proliferative indices and total cell counts
were calculated in multiple sections of 4–6 hearts of each genotype
using ImageJ software (NIH). All the average measurements are
reported with ±standard error of mean (SEM) and statistical
signiﬁcance was determined by Student's t-test (pb0.05).
Chromatin immunoprecipitation (ChIP) assay
Direct Tbx20 binding to chromosomal DNA in vivo was evaluated in
individual mouse hearts dissected from βMHCCre;CC-Tbx20 (DTG) and
littermate CC-Tbx20 (STG) controls at E17.5. DNA/protein complexes
were cross-linked for 10 min in formaldehyde (Sigma) at a ﬁnal
concentration of 1%. The ﬁxed cells were lysed and sonicated twice for
5 s each output 5 (Virsonic 60; Virtis) and a 2 min refractory period. For
immunoprecipitation, cell lysates were incubated with an antibody
against Tbx20 (5 μg; Orbigen) and incubated overnight at 4 °C. Immuno-
precipitation with normal rabbit IgG was used as a negative control. ChIP
assays were performed according to the manufacturer's instructions(EZChIP, Upstate), with the exception that protein A-agarose beads
were used. The immunoprecipitated and input DNA were subjected to
quantitative PCRusing SYBRGreenPCR reagents andMJResearchOpticon
2machine. P-4030 and P-4330 primers were used to amplify the N-myc1
intron 1 promoter region, and P-813 and P-573 primers were used to
amplify the Tbx2 promoter region as previously described (Cai et al.,
2005). Fold enrichment relative to IgG antibody control (negative control)
was calculated using the comparative CT method (ΔΔCt) as described
previously (n=3) (Mandel et al., 2010; Sengupta et al., 2011). Statistical
signiﬁcance was determined by Student's t-test (pb0.05).
Results
βMHCCre-mediated Tbx20 overexpression in differentiated cardiomyocytes
results in thickening of ventricular myocardium
In order to determine the effects of Tbx20 gain-of-function in the
developing heart, mice were generated to express a Cre-inducible
CAG-CAT-Tbx20 (CC-Tbx20) transgene (Fig. 1A). The CAG-CAT-Tbx20
transgene consists of a CAG regulatory element, that includes a CMV
enhancer/β-actin promoter driving the ubiquitous expression of
CAT, ﬂanked by loxp sites, linked to Tbx20. CAT expression from the
transgene was detected by ELISA in multiple organs (heart, brain
and lung) in founder lines (data not shown). In the presence of Cre,
the ﬂoxed CAT gene is deleted and Tbx20 is expressed. Therefore,
conditional overexpression of Tbx20 is achieved in both a spatially
and temporally regulatedmanner in double transgenic (DTG) animals
expressing Cre from βMHC or Nkx2.5 promoters in the presence of the
CC-Tbx20 transgene.
In order to achieve increased Tbx20 expression in differentiated
cardiomyocytes, CC-Tbx20 transgenic mice were mated with
βMHCCre mice (Parsons et al., 2004). βMHCCre-mediated
overexpression of Tbx20 was conﬁrmed by Tbx20 speciﬁc antibody
staining in E14.5 chamber myocardium. βMHCCre activity in the
developing murine heart is apparent throughout the myocardium at
E12.5, E14.5, and E17.5 as indicated by Rosa26R reporter expression
analysis (Supplemental Fig. S1). Tbx20 immunoreactivity, is increased
both in the interventricular septum (IVS in Fig. 1C) and left ventricu-
lar (LV in Fig. 1E) myocardium of the βMHCCre;CC-Tbx20 double
transgenic (DTG) animals compared to the littermate CC-Tbx20 single
transgenic (STG) control (Fig. 1B,D). Tbx20 protein localization, as
detected by immunostaining, is predominantly nuclear in both STG
and DTG animals. Quantitative Western blot analysis reveals
increased expression of Tbx20 in βMHCCre;CC-Tbx20 DTG hearts
beginning at E12.5, with an approximately 3-fold increase in Tbx20
protein expression at E14.5 and E17.5, compared to endogenous
Tbx20 levels (Fig. 1F,G). During development and after birth,
βMHCCre;CC-Tbx20 DTG animals were obtained at the expected
Mendelian ratio, and no embryonic or adult morbidity or mortality
was observed (Table 1).
Histological analysis of E14.5 DTG chamber myocardium overex-
pressing Tbx20 reveals fewer trabeculae in the ventricular myocardi-
um (asterisks, Fig. 1H,I) and an increase in the average number of
nuclei per area of the compact myocardium (Fig. 1J), compared to
littermate STG controls. In addition, the thickness of the compact
myocardium also is signiﬁcantly increased in the E17.5 DTG hearts
as compared to littermate controls (Fig. 1K–M). Thus, βMHCCre-
mediated Tbx20 overexpression results in increased cell number
and thickness of the developing compact myocardium at E14.5–E17.5.
βMHCCre-mediated Tbx20 overexpression promotes cardiomyocyte
proliferation with increased binding to the N-myc1 promoter region in
fetal hearts in vivo
Cardiomyocyte proliferationwas examined in the hearts of βMHCCre;
CC-Tbx20DTGembryos relative to littermate controls. Consistentwith the
Fig. 1. βMHCCre-mediated Tbx20 overexpression in differentiated cardiomyocytes results in thickening of ventricular myocardium. (A) Schematic representation of the CAG-CAT-
Tbx20 (CC-Tbx20) transgene for Cre-dependent Tbx20 expression. The CC-Tbx20 transgene consists of a CAG regulatory element (CMV enhancer linked to chicken β-actin promoter)
that drives the ubiquitous expression of the CAT (chloramphenicol transferase) gene ﬂanked by loxp sites. In the presence of Cre, the CAT gene and translational stop sequences are
deleted and Tbx20 is expressed. (B–E) Overexpression of Tbx20 in E14.5 chamber myocardium of the βMHCCre;CC-Tbx20 double transgenic (DTG) animals is detected by Tbx20
antibody reactivity visualized by DAB staining. Increased Tbx20-positive dark brown/black nuclei (arrows) are apparent in the (C) interventricular septum (IVS) and (E) left ven-
tricular (LV) myocardium of a DTG heart compared to a single transgenic (STG) littermate control (B, D). (F, G) Quantitative Western blot analysis reveals a 1.7-fold, 3.2-fold and
3.4-fold increase of Tbx20 protein expression in E12.5, E14.5 and E17.5 DTG hearts, respectively, compared to littermate STG controls. (H–J) In H&E stained sections, decreased tra-
becular myocardium is apparent in E14.5 DTG LV (compare asterisks in H versus I) and the average number of cells per area of the compact myocardium is increased compared to
littermate control (J) (n=4). (K–L) The thickness of the compact myocardium (black lines) is signiﬁcantly increased in the E17.5 DTG heart as compared to a littermate control in
H&E stained sections. (M) The compact layer thickness was quantiﬁed (n=4) with statistical signiﬁcance determined by Student's t test, where * denotes pb0.05.
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pression, the number of phospho-histone H3 (pHH3) positive nuclei in
MF20 positive cardiomyocytes is increased in DTG embryos, compared
to littermate STG controls at E14.5 (arrowheads, Fig. 2A,B). Quantitation
of these results demonstrates that 20.7% of the nuclei of MF20 positive
cardiomyocytes are also positive for pHH3 in DTG myocardiumoverexpressing Tbx20, compared to 9.3% of the cardiomyocyte nuclei in
STG littermates (Fig. 2C) at E14.5. Thus increased Tbx20 expression
promotes myocardial cell proliferation at E14.5.
N-myc1 is a downstream target gene of Tbx20 in cardiomyocytes
and is a positive regulator of cellular proliferation (Cai et al., 2005;
Davis and Bradley, 1993). N-myc1 expression is increased in
Table 1
The number and percentage (in parentheses) of wild type (WT), single transgenic
(STG), and double transgenic (DTG) individuals obtained from two different crosses
at indicated stages of development. The expected Mendelian ratio is indicated in bold
and N represents the total number of individuals analyzed for each stage.
Nkx2.5Cre;CC-Tbx20
Stage N WT (25%) STG (50%) DTG (25%)
E9.5 47 10 (21.3%) 26 (55.3%) 11 (23.4%)
E10.5 54 15 (27.8%) 32 (59.2%) 7 (13%)
E12.5 44 13 (30%) 31 (70%) 0
E14.5 34 14 (41%) 20 (59%) 0
βMHCCre; CC-Tbx20
Stage N WT (25%) STG (50%) DTG (25%)
E12.5 35 6 (17.1%) 19 (54.3%) 10 (28.6%)
E14.5 74 14 (19.0%) 40 (54.0%) 20 (27.0%)
E17.5 65 19 (29.2%) 35 (53.8%) 11 (17.0%)
Adult 44 10 (22.7%) 22 (50.0%) 12 (27.3%)
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detected by ISH (arrows, Fig. 2D,E). Expression of N-myc1 mRNA is
increased by 3.8-fold in E14.5 DTG hearts overexpressing Tbx20,Fig. 2. βMHCCre-mediated Tbx20 overexpression promotes cardiomyocyte proliferation wit
vivo. (A–B) Cardiomyocyte cell proliferation was detected by phospho-histone H3 (pHH3) n
(arrowheads in B) compared to littermate controls (arrowheads in A). (C) Quantitation of th
overexpressing Tbx20 compared to littermate controls (n=4). (D–F) Increased expression
in DTG myocardium overexpressing Tbx20 (compare D and E). (F) Observed differences in N
E14.5 DTG hearts relative to STG controls, set to 1.0 (n=3). (G) ChIP assays performed at E
consensus site within intron 1 of the N-myc1 promoter region in DTG hearts compared to
antibody control as determined by qPCR (n=3). Statistical signiﬁcance was determined byrelative to controls, as determined by qRT-PCR (Fig. 2F). In cardio-
myocytes, Tbx20 promotes cell proliferation through activation and
binding to regulatory elements of N-myc1 and Tbx2 genes (Cai et al.,
2005). Therefore, ChIP assays were performed to determine if Tbx20
binding to the promoter region of N-myc1 is increased in association
with increased gene expression in fetal cardiomyocytes overexpressing
Tbx20. In E17.5 DTG hearts, Tbx20 binds to the promoter region of N-
myc1 with 14.5-fold enrichment over IgG controls, compared to 3-fold
enrichment in STG littermates (Fig. 2G). Interestingly, no difference in
Tbx20 binding to the Tbx2 promoter region was observed by ChIP
analysis, consistent with no observed change in gene expression in DTG
versus STG hearts (data not shown). Together, these data suggest that
Tbx20 directly binds and induces N-myc1 expression while also promot-
ing cardiomyocyte proliferation in βMHCCre;CC-Tbx20 hearts in vivo.
Bmp10 expression and pSmad1/5/8 signaling is increased in differentiated
fetal cardiomyocytes overexpressing Tbx20
Cardiomyocyte proliferation during heart chamber maturation is
dependent on Bmp10 (Chen et al., 2004). Therefore, Bmp10 mRNA
expression was evaluated in DTG hearts overexpressing Tbx20.
Expression of Bmp10 transcripts is increased in DTG myocardium
overexpressing Tbx20, as detected by ISH, compared to littermateh increased binding to the N-myc1 promoter region in βMHCCre;CC-Tbx20 fetal hearts in
uclear staining in MF20 positive cells at E14.5 in βMHCCre;CC-Tbx20 (DTG) myocardium
ese results demonstrates a signiﬁcant increase in proliferative indices of cardiomyocytes
of N-myc1, a known downstream target of Tbx20 in cardiomyocytes, is apparent by ISH
-myc1 gene expression were further conﬁrmed by qRT-PCR analysis of mRNA levels in
17.5 demonstrate increased Tbx20 binding (14.5-fold) to a previously identiﬁed T-box
littermate STG controls (3-fold). Graphs represent fold enrichment relative to the IgG
Student's t test, where * denotes pb0.05.
Fig. 3. Bmp10 expression and pSmad1/5/8 signaling are increased in βMHCCre;CC-Tbx20 fetal hearts overexpressing Tbx20. (A–B) Increased expression of Bmp10 transcripts is
detected in the DTG myocardium overexpressing Tbx20 by ISH (arrows in A, B). (C) Observed differences in gene expression were conﬁrmed by qRT-PCR analysis of Bmp10
mRNA levels in E14.5 DTG hearts relative to levels in STG controls, which were set to 1.0 (n=3). (D–G) The presence of pSmad1/5/8 was assessed by immunoﬂuorescence and
confocal microscopy. pSmad1/5/8 immunoreactivity (green nuclei) is increased in MF20 positive cardiomyocytes (red) and throughout the ventricles overexpressing Tbx20 in
both E14.5 (arrowheads in E) and E17.5 (arrowheads in G) DTG hearts, compared to the littermate STG controls (arrowheads in D and F, respectively). (H–I) Quantitation of
pSmad1/5/8 protein by Western blot (n=6) demonstrates a 2.1-fold up-regulation in E14.5 DTG hearts, compared to littermate STG controls. Statistical signiﬁcance was deter-
mined by Student's t test, where * denotes pb0.05.
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2.9-fold in E14.5 DTG hearts relative to littermate STG controls, as
detected by qRT-PCR (Fig. 3C). Increased BMP signaling in the heart
also is apparent as an increase in the number of phospho-Smad1/5/
8 (pSmad1/5/8) positive nuclei at E14.5 and E17.5, compared to STG
controls (Fig. 3D–G). Increased pSmad1/5/8 positive nuclei are appar-
ent in MF20-positive and -negative cells in the DTG ventricles, indic-
ative of increased BMP signaling in multiple cell types. Quantitation of
pSmad1/5/8 protein expression by Western blot demonstrates a 2.1-
fold increase in total pSmad1/5/8 protein levels in E14.5 DTG hearts,
compared to littermate STG controls (Fig. 3H–I). In contrast,
pSmad1/5/8 expression levels were unchanged in Nkx2.5Cre;CC-
Tbx20 embryonic ventricular cardiomyocytes (E9.5) compared to lit-
termate STG controls (Supplemental Fig. S2A–D). Thus, Tbx20 pro-
motes Bmp10 expression and pSmad1/5/8 signaling speciﬁcally
associated with increased cell proliferation of fetal, but not embryon-
ic, cardiomyocytes.
βMHCCre-mediated Tbx20 overexpression represses Tbx2, while promoting
Tbx5, connexin 40 (Cx40) and connexin 43 (Cx43), expression in ventricular
cardiomyocytes
Localized expression of Tbx2 and Tbx5 was examined in hearts
with Tbx20 overexpression. In βMHCCre;CC-Tbx20 DTG hearts, theexpression of Tbx2 is reduced in the AVC myocardium at E14.5,
compared to normal expression in the littermate control heart, as
detected by ISH (Fig. 4A,B). In contrast, Tbx5 expression is induced
throughout the septum (IVS) and in the ventricles in DTG hearts
compared to localized expression in the littermate control heart at
E18.5 (Fig. 4C–F). Consistent with previous reports (Hatcher et al.,
2000), Tbx5 expression is detected at the epicardial surface of E18.5
STG hearts, and decreased epicardial expression of Tbx5 was noted
in multiple E18.5 DTG hearts (Fig. 4E,F). Thus Tbx20 overexpression
leads to decreased Tbx2 expression in the AVC and increased
expression of Tbx5 throughout the developing ventricles, but not
epicardium, of βMHCCre;CC-Tbx20 DTG fetuses in vivo.
Gene expression of T-box downstream target genes Cx40 and Cx43,
expressed in the cardiac conduction system (CCS), was examined in
βMHCCre;CC-Tbx20 DTG hearts at E18.5 (Christoffels et al., 2010). At
this stage, Cx40 expression is normally restricted to the ventricular
conduction tissues, and Cx43 is expressed in the trabecular and, to a
lesser extent, the compact myocardium (Coppen et al., 2003). In
βMHCCre;CC-Tbx20 DTG hearts, the expression of both the Cx40 and
Cx43 transcripts is increased throughout the full thickness of the
ventricular walls, including the interventricular septum (Fig. 4G–N).
In contrast, expression of Nppa, which is regulated by multiple Tbx
factors including Tbx5 and Tbx2 (Habets et al., 2002), is apparently
unaltered in the DTG trabecular myocardium, compared to a littermate
Fig. 4. βMHCCre-mediated Tbx20 overexpression represses Tbx2, while inducing expression of Tbx5, connexin40, and connexin43 in differentiated cardiomyocytes. (A–F) Expression
of Tbx2 and Tbx5 transcripts was evaluated in the βMHCCre;CC-Tbx20 (DTG) myocardium overexpressing Tbx20 by ISH. In E14.5 DTG hearts, the expression of Tbx2 is reduced along
the AV canal myocardium (B, arrow) compared a littermate STG control (A, arrow). In E18.5 DTG hearts, Tbx5 expression is increased throughout the interventricular septum (IVS)
and in the ventricles (D, F, arrows) compared to restricted expression in the littermate control heart (C, E, arrows). Expression of Cx40 (H, J) and Cx43 (L, N) is increased in the DTG
myocardium (arrows) compared to expression in STG littermate controls (G, I and K, M). In contrast, Nppa expression is unchanged in the DTG trabecular myocardium compared to
the littermate control heart (compare O and P, arrows). (Q) Observed differences in gene expression were further validated by qRT-PCR in DTG hearts relative to STG controls
(n=3). Statistical signiﬁcance was determined by Student's t test, where * denotes pb0.05.
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further conﬁrmed by qRT-PCR (Fig. 4Q). Since altered expression of
Connexin genes would be expected to affect the CCS, AV conduction
system function was evaluated in adult hearts overexpressing Tbx20
by surface electrocardiography (ECG). However no signiﬁcant changes
in AV conduction system amplitudes or intervals were detected, at
least at the baseline level, in Tbx20 DTG adult animals compared to
littermate controls (data not shown). Thus Tbx20 overexpression in
ventricular cardiomyocytes at fetal stages results in decreased expres-
sion of Tbx2 and increased expression of Tbx5, with widespread
increased expression of Connexins (Cx40 and Cx43) beyond the CCS.
Nkx2.5Cre-mediated Tbx20 overexpression results in a smaller heart
with decreased expression of Tbx5, but apparently normal expression
levels of chamber maturation genes
Nkx2.5Cre;CC-Tbx20 DTG mice were generated in order to
determine effects of increased Tbx20 function in embryonic
cardiomyocytes during the early stages of heart chamber formation
(Moses et al., 2001). Nkx2.5Cre;CC-Tbx20 DTG embryos exhibit
growth retardation and obvious lethality by E10.5 (Table 1), therefore
all the experimental analyses were performed at E9.5. Nkx2.5Cre-
mediated overexpression of Tbx20 in embryonic cardiomyocytes
results in a smaller heart size in E9.5 DTG embryos (black arrowheadsin Fig. 5A,B), compared to littermate control embryos (white
arrowheads in Fig. 5A,B). In heart tissue sections of the DTG and the
littermate STG control embryos, cardiomyocyte differentiation is
apparent by MF20 immunoreactivity (Fig. 5D,G), but the ventricles
are thin with decreased trabeculation in Nkx2.5Cre;CC-Tbx20 embryos
at E9.5 (Fig. 5C,F). In addition, endocardial cushion formation seems
to be unaffected in E9.5 DTG hearts as evidenced by similar Twist1-
antibody reactivity in cushion mesenchymal cells compared to
littermate control hearts (Fig. 5E,H). Tbx20 overexpression in DTG
embryos was conﬁrmed by increased Tbx20 antibody reactive nuclei
in the DTG ventricular myocardium, including LV, RV and OFT regions
compared to a littermate control heart (Fig. 5J,L). Direct cell counts
reveal that approximately 38.8% MF20-positive cardiomyocytes are
also positive for Tbx20, compared to 16% Tbx20 and MF20 positive
cardiomyocytes in littermate controls (Fig. 5M). Quantitative
Western blot analysis reveals a 3.4-fold overexpression of Tbx20
protein in E9.5 DTG hearts, compared to littermate STG controls
(Fig. 5N,O). Thus induced expression of Tbx20 in the primitive heart
tube leads to reduced cardiac growth, which is in contrast to the
increased cardiac growth observed in the ventricular myocardium of
βMHCCre;CC-Tbx20 DTG embryos at E14.5.
Mice lacking Tbx20 fail to activate chamber lineage maturation
genes (Cai et al., 2005; Singh et al., 2005; Stennard et al., 2005).
Therefore expression of indicators of chamber differentiation was
Fig. 5. Nkx2.5Cre-mediated Tbx20 overexpression results in a smaller heart with apparently normal endocardial cushion formation. Nkx2.5Cre-mediated overexpression of Tbx20
results in a smaller heart in E9.5 DTG embryos (black arrowheads in A and B) compared to somite-matched STG embryos (white arrowheads in A and B), displayed in both left (A)
and right (B) lateral views. Histological (H&E) and MF20 antibody staining also reveal the smaller heart size in Nkx2.5Cre;CC-Tbx20 (DTG) embryos (compare C versus F and D versus
G). The generation of mesenchymal cells and expression of Twist1, indicative of EMT, is apparently normal in the DTG endocardial cushion (arrowhead in H) compared to littermate
STG control (arrowhead in E). Tbx20-speciﬁc antibody staining reveals Tbx20 overexpression as indicated by positive green nuclei (arrowheads in L), throughout LV, RV and OFT
regions of the DTG myocardium compared to the littermate control (arrowheads in J), as detected by immunoﬂuorescence and confocal imaging. (M) Direct cell counts reveal that
38.8% of MF20 positive cardiomyocytes are also positive for Tbx20 in DTG ventricular chamber myocardium compared to 16% in littermate controls. (N, O) Quantitative Western
blot analysis reveals a 3.4-fold increase of Tbx20 protein expression in E9.5 DTG hearts, compared to littermate STG controls (n=6–8). Statistical signiﬁcance is determined by Stu-
dent's t test, where * denotes pb0.05.
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expression of Tbx2 is decreased in the E9.5 AVC myocardium overex-
pressing Tbx20, compared to its normal expression in the littermate
control AVC myocardium (Fig. 6A,B). The expression of Tbx5 is also
down-regulated throughout the E9.5 mutant myocardium, compared
to its strong expression in the STG control myocardium (Fig. 6C,D). In
contrast, expression of Bmp10 is comparable in the E9.5 DTG mutantheart, compared to its normal expression in the STG littermate
control (Fig. 6E,F). Likewise, the expression of chamber differentia-
tion markers Nppa, Smpx, and MLC2v is similar in the DTG and STG
embryos (Fig. 6G–L). Gene expression analysis by qRT-PCR conﬁrmed
decreased expression of Tbx5 and unchanged expression of Bmp10,
Nppa, Smpx and Mlc2v in E9.5 DTG hearts relative to littermate STG
controls (Fig. 6M). Together these data demonstrate that the
Fig. 6. Nkx2.5Cre-mediated Tbx20 overexpression leads to decreased expression of Tbx5 but normal induction of chamber differentiation markers. Cardiac gene expression was
evaluated by ISH. The expression of Tbx2 is apparently decreased in the AVC myocardium overexpressing Tbx20 (arrows in B) compared to its normal expression in the littermate
control heart (arrows in A). The expression of Tbx5 (arrows in D) is also decreased throughout the DTG myocardium, compared to littermate control (arrows in C). In contrast,
Bmp10 expression in trabecular cardiomyocytes in the DTG heart is comparable to the littermate control (arrows in E and F). Nppa and Smpx are expressed in the DTG myocardium
overexpressing Tbx20 (arrows in H and J), as well as in control littermates (arrow in G and I). Likewise the expression ofMlc2v, which marks the developing ventricle, is apparent in
DTG hearts (arrow in L) and littermate STG controls (arrow in K). (M) Expression of genes analyzed by ISH was quantiﬁed in DTG relative to STG hearts by qRT-PCR of RNA isolated
at E9.5 (n=5). Statistical signiﬁcance is determined by Student's t test, where * denotes pb0.05.
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myocytes results in decreased Tbx5 expression, but does not affect
expression of markers of chamber myocardial maturation.
Nkx2.5Cre-mediated Tbx20 overexpression leads to decreased prolifera-
tion with induction of p21CIP1 in cardiomyocytes
Cardiomyocyte proliferation and expression of cell cycle regulatory
genes were examined in Nkx2.5Cre;CC-Tbx20 DTG hearts. Co-labeling
of pHH3 and MF20 demonstrates reduced cardiomyocyte proliferation
in E9.5 DTG embryos, compared to littermate STG controls (Fig. 7A,B).
Quantitation of these results demonstrates that 18.5% of MF20 positive
cardiomyocyte cell nuclei are also positive for pHH3 in DTG myocardi-
um, compared to 36.6% MF20 and pHH3 positive nuclei in STG controls
(Fig. 7C). In contrast, the percent of nucleiwith pHH3 immunoreactivity
in the endocardial endothelial cell layer is unchanged in DTG versus STG
hearts (data not shown). Consistentwith reduced cardiomyocyte prolif-
eration, expression of the cyclin dependent kinase (CDK) inhibitor
p21CIP1 is increased in DTG myocardium overexpressing Tbx20,
compared to the littermate control myocardium as detected by
immunostaining and qRT-PCR (Fig. 7D–F,I). Expression of additional
cell cycle regulatory genes that promote proliferation, including cyclin
A2, cyclin D1, and cyclin E1, also is reduced in Nkx2.5Cre;CC-Tbx20 as
detected by qRT-PCR. However mRNA expression of another CDK
inhibitor (CKI), p27KIP1 remains unchanged in E9.5 DTG hearts com-
pared to controls (Fig. 7I). In contrast to βMHCCre;CC-Tbx20DTG hearts,
N-myc1 gene expression is decreased in the E9.5 Nkx2.5Cre;CC-Tbx20DTG ventricular myocardium as detected by ISH and qRT-PCR
(Fig. 7G–I), consistent with reduced cardiomyocyte proliferation in
these embryos.
Tbx20 overexpression inhibits activation of ERK1/2 MAPK in Nkx2.5Cre;
CC-Tbx20 embryonic cardiomyocytes in vivo
In order to further characterize the differential effects of Tbx20 on
embryonic versus fetal cardiomyocyte proliferation, pERK1/2 expres-
sion was evaluated in E9.5 Nkx2.5Cre;CC-Tbx20 DTG hearts compared
to littermate controls by antibody staining (A–D) and Western blot
(E–F) analyses. At E9.5, dpERK is normally active in the myocardium
and has been implicated as a downstream mediator of Neuregulin
signaling (Lai et al., 2010). In Nkx2.5Cre;CC-Tbx20 DTG hearts,
dpERK expression is reduced throughout the ventricular chamber
myocardium, compared to control hearts (Fig. 8A–D). Quantitation
of these results by Western blot analysis demonstrates that the ratio
of dpERK/total ERK expression is reduced by 42% in Nkx2.5Cre;CC-
Tbx20 hearts, relative to control hearts, and that total ERK protein
levels are unchanged (Fig. 8E,F). Together, these data indicate that
ERK activation is decreased with Tbx20 overexpression at E9.5.
However, the expression of Nrg1, mRNA predominant in endothelial
lineage, is apparently unaffected by Tbx20 overexpression as detected
by qRT-PCR and IHC (data not shown). In contrast to the decreased
expression in Nkx2.5Cre;CC-Tbx20 DTG hearts, dpERK activation is
not decreased in βMHCCre;CC-Tbx20 ventricular cardiomyocytes,
compared to littermate STG controls, consistent with the observed
Fig. 7. Nkx2.5Cre-mediated Tbx20 expression leads to decreased proliferation with increased expression of p21CIP1 in cardiomyocytes. (A–C) The number of pHH3 positive cardi-
omyocyte nuclei in the E9.5 Nkx2.5Cre;CC-Tbx20 DTG myocardium (arrowheads, B) compared to the littermate control (A) is decreased as visualized by immunoﬂuorescence and
confocal microscopy and as quantiﬁed in (C) (n=4). Insets in A and B show ventricular chamber myocardium labeled with MF20 and pHH3 antibodies and ToPro3 nuclear counter
stain. (D–E) Increased immunostaining of p21CIP1 (green nuclei) is detected in the DTG myocardium overexpressing Tbx20 (arrowheads, E) compared to the littermate STG control
heart (D) and is quantiﬁed in F (1.2% in STG versus 27.3% in DTG). Insets in D and E represent ventricular chamber myocardium labeled with p21CIP1 antibody and ToPro3. (G–H) N-
myc1 gene expression is decreased in the E9.5 DTG ventricular myocardium overexpressing Tbx20 (arrow in H), compared to its expression in the littermate control myocardium
(arrow in G), as detected by ISH. (I) Expression of cell cycle regulatory genes p21CIP1, p27KIP1 cyclin A2, cyclin D1, cyclin E1, and N-myc1was evaluated in E9.5 DTG hearts by qRT-PCR
(n=5). Statistical signiﬁcance of observed differences was determined by Student's t test, where * denotes pb0.05.
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Together, these data demonstrate that increased Tbx20 protein levels
inhibit dpERK activation in embryonic (E9.5), but not fetal (17.5), car-
diomyocytes in vivo.
Discussion
Here we demonstrate that Tbx20 overexpression in the primitive
heart results in decreased cardiomyocyte cell proliferation with
decreased N-myc1 expression at E9.5. Previous studies reported that
mice with loss of Tbx20 also exhibit reduced cardiomyocyte prolifer-
ation and decreased expression of N-myc1 at E10.5 (Cai et al., 2005;
Singh et al., 2005; Stennard et al., 2005). Thus, increased or decreasedTbx20 expression similarly affects cardiomyocyte proliferation and N-
myc1 gene expression during the initial stages of heart chamber
maturation. Nkx2.5Cre-mediated overexpression of Tbx20 also
results in reduced expression of multiple cyclin genes (A2, D1 and
E1), as well as increased expression of the cell cycle inhibitor
p21CIP1, consistent with the observed reduction in cardiomyocyte
proliferation. Neuregulin signaling has been implicated chamber-
speciﬁc gene regulation and in ventricular trabeculation through
dpERK activation (Lai et al., 2010; Stennard et al., 2005; Woldeyesus
et al., 1999). Similar to loss of Nrg1 function, Tbx20 overexpression
leads to decreased dpERK expression and decreased cell proliferation.
However, unlike embryos with Nrg1 or Tbx20 loss-of-function, markers
of chamber myocardial maturation are normally induced with Tbx20
Fig. 8. Nkx2.5Cre-mediated overexpression of Tbx20 results in decreased dpERK ex-
pression in embryonic cardiomyocytes. (A–D) Expression of the diphosphorylated
form of ERK1/ERK2 (dpERK) in E9.5 chamber myocardium is detected by dpERK-
speciﬁc antibody reactivity visualized by DAB staining. Panels C and D represent higher
magniﬁed views (40× objective) of the LV region from panels A and B (20× objective),
respectively. Reduced dpERK reactivity (brown/black nuclei) is apparent in the ventric-
ular cardiomyocytes (arrowheads in D) of a DTG embryo compared to the STG litter-
mate control (arrowheads in C). (E–F) dpERK expression was quantiﬁed by Western
blot analysis as the ratio of dpERK to total ERK protein in E9.5 DTG hearts compared
to littermate STG controls (n=6–8). Statistical signiﬁcance is determined by Student's
t test, where * denotes pb0.05.
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determinant in cardiomyocyte cell proliferation and lineagematuration
in embryonic cardiomyocytes.
In contrast to embryonic cardiomyocytes, βMHCCre-mediated
Tbx20 overexpression in fetal ventricular cardiomyocytes (E12.5-
E17.5) promotes cell proliferation. Tbx20 overexpression at fetal
stages leads to increased expression of N-myc1, Bmp10, pSmad1/5/8,
and Tbx5, all of which promote cardiomyocyte cell proliferation
(Brown et al., 2005; Cai et al., 2005; Chen et al., 2004; Hatcher et al.,
2001). N-myc1 has been identiﬁed as a direct downstream target of
Tbx20, and increased Tbx20 binding to T-box responsive elements
in the N-myc1 promoter region is observed in fetal cardiomyocytes,
supporting a direct transcriptional activation mechanism (Cai et al.,
2005). However, N-myc1 gene expression is not induced in embryonic
cardiomyocytes with Tbx20 overexpression, providing evidence for a
more complex regulatory mechanism. Likewise Bmp10 expression and
pSmad1/5/8 activation, required for fetal cardiomyocyte cell prolifera-
tion (Chen et al., 2004, 2006), are increased in response to Tbx20
overexpression at fetal, but not embryonic, stages. Tbx5 also promotes
cell proliferation in cardiomyocytes, and the observed increase in Tbx5
expression with Tbx20 overexpression at E14.5, but not E9.5, could
contribute to the stage-speciﬁc increase in cell proliferation of fetal
cardiomyocytes (Brown et al., 2005; Hatcher et al., 2001). Together
these analyses demonstrate that embryonic and fetal cardiomyocytes
are distinct in their responses to Tbx20 overexpression, which may be
indicative of stage-speciﬁc differential regulation of cofactors orintersecting signaling pathways. However, further studies are necessary
to fully characterize these complex regulatory mechanisms.
Tbx20 has been implicated as both an upstream regulator and
downstream target of BMP signaling. Here we demonstrate that
Tbx20 overexpression in fetal cardiomyocytes leads to increased
Bmp10 expression and pSmad1/5/8 activation. In addition, Bmp10 is
necessary and sufﬁcient to activate Tbx20 expression in the fetal
myocardium, and a conserved Smad binding site mediates Bmp10
induction of Tbx20 proximal promoter sequences in cell culture
studies (Zhang et al., 2011). Together, these data provide evidence
for a feedforward regulatory mechanism of Tbx20 and Bmp10 during
heart chamber maturation. Likewise, genetic deletion of Tbx20
speciﬁcally from the atrioventricular canal (AVC) myocardium results
in downregulation of Bmp2, and Bmp2 induces Tbx20 expression in
endocardial cushion cells supporting a similar feedforward mechanism
in endocardial cushion development (Cai et al., 2011; Shelton and
Yutzey, 2007). Additional feedback regulatory mechanisms in BMP/
Smad signaling occur at the protein level since Tbx20 interacts with
Smad1/5 proteins to attenuate their transcriptional regulatory activity
(Singh et al., 2009). Together these studies demonstrate that Tbx20
intersects with BMP signaling in multiple ways to regulate diverse
aspects of heart formation, including myocardial cell proliferation and
endocardial cushion development.
Several T-box transcription factors, including Tbx2, Tbx3, and
Tbx5, coordinately regulate connexin gene expression in the CCS,
and Cx40 is a direct downstream target gene of Tbx5 (Aanhaanen et
al., 2011; Bakker et al., 2008; Bruneau et al., 2001; Moskowitz et al.,
2004). However, Tbx20 function in CCS development has not
previously been reported. Tbx20 overexpression in fetal ventricular
cardiomyocytes leads to increased expression of Tbx5, Cx40, and
Cx43 throughout the ventricular myocardium. Since Cx40 and Cx43
are regulated by multiple T-box transcription factors, it is likely that
increased expression of Tbx20 disrupts the balance of repressive
and activating T-box factors on these gene regulatory elements
leading to their increased expression in the ventricular myocardium.
However the dysregulation of connexin gene expression is apparently
insufﬁcient to cause cardiac arrhythmias in adult animals (data not
shown). It is striking to note that expression of Nppa, which is
responsive to Tbx5, Tbx2, and Tbx20, is apparently unaffected by
Tbx20 overexpression in fetal ventricular cardiomyocytes (Habets et
al., 2002; Plageman and Yutzey, 2004; Stennard and Harvey, 2005).
Thus T-box regulation of conduction gene expression is more
sensitive to increased Tbx20 than is the expression of chamber
myocardium genes, such as Nppa, in the fetal myocardium. Together,
these results demonstrate that ventricular cardiomyocytes with
increased Tbx20 expression exhibit enhanced molecular features of
the CCS, including increased expression of Tbx5, Cx40 and Cx43.
In human patients, TBX20 gain- and loss-of-function mutations are
associated with a wide spectrum of cardiovascular abnormalities,
including cardiomyopathies and congenital valvuloseptal defects
(Kirk et al., 2007; Posch et al., 2010). Defects in prenatal heart
chamber growth can occur in individuals with a TBX20 loss-of-
function mutation, consistent with the importance of Tbx20 function
in cardiac growth during development (Kirk et al., 2007). Gain- and
loss-of-function mutations in TBX20 also are associated with dilated
cardiomyopathy in adult and pediatric patients (Kirk et al., 2007;
Posch et al., 2010). Arrhythmias and sudden death have been
reported in patients with a TBX20 mutation, and conditional loss of
Tbx20 in adult mice results in severe cardiomyopathy associated
with arrhythmias and death (Qian et al., 2008; Shen et al., 2011).
Here, we provide evidence that increased levels of Tbx20 can affect
cardiac conduction system gene expression during development,
further supporting TBX20 as a candidate gene in hereditary
conduction system anomalies. The combination of human genetic
analyses and studies in animal model systems has linked Tbx20
function to congenital cardiac malformations, conduction system
245S. Chakraborty, K.E. Yutzey / Developmental Biology 363 (2012) 234–246anomalies, and adult cardiomyopathy. Thereforemanipulation of Tbx20
function or intersecting regulatory pathways could be exploited thera-
peutically. However these studies should proceedwith caution because
increased or decreased Tbx20 function in cardiomyocytes can lead to
pleiotropic downstream effects on cell proliferation, lineage matura-
tion, or conduction mediated by Tbx20 and its complex interacting reg-
ulatory factors.
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